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antidepressants only, $35,099 for psychotherapy only, $33,032 for both and $34,041 
for those receiving no depression treatment. Adjusted linear mixed model analy-
sis revealed that as compared to no depression treatment, depression treatment 
with antidepressants only, psychotherapy only and by both antidepressants and 
psychotherapy reduced total healthcare expenditures by 17%(p-value< 0.001), 
22%(p-value< 0.001) and 28%(p-value< 0.001) respectively. CONCLUSIONS: 
Depression treatment reduced healthcare expenditures suggesting that among 
individuals with T2DM who develop depression, prioritizing treatment for depres-
sion can result in economic benefits.
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OBJECTIVES: Type 2 diabetes mellitus (DM) accounts for over 90% of all diagnosed 
diabetes cases. Hyperglycemia is an important risk factor for diabetic compli-
cations, supporting the use of glucose-lowering agents in the treatment of dia-
betes. Among glucose-lowering agents to treat type 2 DM are oral antidiabetic 
(OAD) agents. The objective of this study was to evaluate the Canadian market 
for OAD agents since 2008, soon after dipeptidyl peptidase (DPP)-4 inhibitors 
were introduced. METHODS: Data on retail prescriptions and on drugstore and 
hospital purchases of OAD agents in Canada were obtained from IMS Brogan. 
Number of prescriptions and purchases (in $Can) were collected for 2008, 2012 
and 2014. RESULTS: Total number of prescriptions for OAD agents in Canada 
amounted to 13.6 million, 20.5 million and 23 million in 2008, 2012, and 2014, 
respectively. Contribution of the two OAD agents mainly prescribed, metformin 
and sulfonylureas, decreased during this period while percentage of prescriptions 
for DPP-4 inhibitors over total OAD agents increased from 0.075% to 6.5% and to 
14.5%, respectively, driven by the increase in prescriptions of sitagliptin, sitaglip-
tin/metformin, saxagliptin, and linagliptin. Total drugstore and hospital purchases 
for OAD agents in Canada reached $394.2 million, $418.7 million and $520.9 million 
in 2008, 2012, and 2014, respectively. Percentage of purchases of DPP-4 inhibitors 
over total OAD agents markedly increased during this period, from 0.5% to 34.1% 
and to 64.1%, respectively. CONCLUSIONS: OAD agents represent a market of 
more than half a billion dollars in Canada; this will likely continue to grow due to 
the increasing occurrence of cases of type 2 DM in the general population. Since 
their introduction in 2008, DPP-4 inhibitor use has grown rapidly so that in 2014, 
they captured approximately one-sixth of prescriptions and, at almost two-thirds 
of purchases, were the market leaders among OAD agents.
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OBJECTIVES: Info-Diabetics’ is becoming an imperative approach in E-health to 
stipulate the diabetic patient care and management. In this study we tried to get an 
overview for application of cellular phone text messaging over adolescent diabetic 
patients (ADPs). The major objective of this study was to test whether adding cellular 
application for patient care compared with control cases would reduce Glycated 
Hemoglobin (HbA1c). METHODS: Eleven ADPs (study cases, n= 11) were selected for 
mobile phone coaching through text messaging, to consultants. ADPs of the control 
site (n= 09) were continued with their standard diabetes health care from consult-
ants. Primarily ADPs were enquired for demographic and social characteristics, 
frequency of cellular phone use, general health information and diagnosis of type 
2 diabetes. Further the level of Hb1Ac, in both the groups, was measured in a regular 
interval of 45 days. After 225 days, percentage of mean improvement in Hb1Ac level 
was compared between cellular users and control cases. RESULTS: More than 3% 
improvement in Hb1Ac was observed among the patients having mobile phone and 
they made regular interaction with consultant. The differences were very small but 
a trend of positive improvement was observed among ADPs using cellular phone’s 
text messaging. CONCLUSIONS: Result indicated that info-diabetic approach may 
contribute to minimize complexities in medical care and the cautious use of cel-
lular phone technology in the form of text messaging would be an asset for self 
care management in ADPs.
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BACKGROUND: In a recent commentary (Basu ERPOR2015), we proposed a solution 
to financing cures in the presence of multiple payers by recommending develop-
ment of a tradable new currency, HealthCoin, which would convert the incremental 
consequences produced by certain well-established cures to a common numeraire 
that can be traded with real dollars in the marketplace among private and pub-
lic payers. OBJECTIVES: To develop the theory behind the provision of a tradable 
HealthCoin for a cure for diabetes between a private payer that provides coverage 
for non-elderly adults, and a public payer (e.g. Medicare) covering the elderly popu-
lation. METHODS: We identify the conditions under which the either payer lacks 
incentive to pay for the cure and where a HealthCoin can overcome these incentives 
problems. We illustrate this theory using empirical estimates for cost-savings and 
life-years gain generated by a cure for diabetes. RESULTS: We find that the precise 
condition required for the valuation of a HealthCoin that would incentivize the 
public payer to offer the HealthCoin as a payment to the private payer, which in turn 
would now have the incentive to purchase the cure, is min{INMBMedicare, PCure} ≥ 
two subsequent prescriptions.   Time to discontinuation was analyzed using 
Kaplan-Meier and Cox proportional hazards regression, including demograph-
ics, treatment background, and diabetes-related complications/comorbidities as 
covariates. RESULTS: 66,206 patients (mean age 52.6 years; 50% male; median/
maximum follow-up, 10.1/19.0 months) were identified in the Truven database. 
After one year, the percentage of patients still on treatment was significantly 
higher with canagliflozin 100 mg (n=7,445; 64.0%) and 300 mg (n=4,486; 65.0%) 
versus DPP-4 inhibitors (30.2% [linagliptin] to 50.1% [sitagliptin]) and GLP-1 ago-
nists (24.3% [exenatide] to 43.0% [liraglutide]) (P <0.0001 for all comparisons).  The 
adjusted hazard ratio (HR) for time to discontinuation for canagliflozin 100 mg 
(reference) and 300 mg (HR=0.92 [0.86;0.99]) was significantly lower versus DPP-4 
inhibitors and GLP-1 agonists: sitagliptin (n=29,426; HR=1.28 [1.22;1.34]); saxagliptin 
(n=1,566; HR=2.01 [1.86;2.16]); linagliptin (n=1,432; HR=2.08 [1.92;2.24]); exenatide 
(n=2,376; HR=2.59 [2.41;2.77]); exenatide long-acting (n=5,922; HR=1.46 [1.40;1.52]); 
liraglutide (n=17,690; HR=1.23 [1.20;1.27]).  Being younger, male, and being on 
monotherapy were associated with higher discontinuation risk.  HRs were stable 
across sensitivity analyses using alternative discontinuation definitions.  Analyses 
from Optum were generally consistent with these results. CONCLUSIONS: These 
analyses indicate that patients who received canagliflozin versus DPP-4 inhibi-
tors or GLP-1 agonists remained on their therapy longer, which may reflect better 
effectiveness and/or tolerability.
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OBJECTIVES: Within the US type 2 diabetes mellitus (T2DM) treatment, following 
metformin failure, is thought to be quite variable given a broad treatment arma-
mentarium. We therefore, sought to determine if newer agent classes or patient 
age influenced prescribing patterns. METHODS: De-identified prescriptions from 
the T2DM analytic platform of the Humedica electronic health records database 
were described, 1/1/2010-6/30/2014. RESULTS: Selection criteria were met by 193,592 
T2DM patients, of whom 71,452 (37%) were ≥ 65 years-old (“elderly”). Of first-line pre-
scriptions, metformin was the most common (59%) followed by SUs (13%), basal (9%) 
and other insulins (9%), DDP4s and DDP4 fixed-dose-combinations (5%), GLP1 (2%), 
TZDs (2%); others ≤ 1%. Metformin first-line monotherapy was prescribed to 140,055 
patients. Of these, 112,387 (80%) remained on monotherapy or discontinued without 
receiving subsequent prescriptions, only 20% progressed to a second-line therapy. 
Top second-line prescriptions were for: metformin+SU (30%), SU monotherapy 
(16%), metformin+DPP4 (9%), DPP4 monotherapy (6%), metformin+basal insulin (4%), 
metformin+GLP1 (4%), DPP4 FDC (4%), metformin+other insulin (3%); others < 3%. 
The elderly received first-line prescriptions for: metformin (49%), SU (18%), insulins 
(basal, 10%; other, 11%), DPP4 FDCs (6%), TZDs (3%), other FDCs (1%), and GLP1s 
(1%). Of the 42,852 elderly receiving metformin monotherapy, 81% either continued 
metformin monotherapy or discontinued without receiving subsequent prescrip-
tions, with 19% progressing to second-line. Top second-line prescriptions among 
the elderly were: metformin+SU (29%), SU monotherapy (22%), metformin+DPP4 
(9%), DPP4 monotherapy (8%), metformin+other insulin (4%), metformin+basal 
insulin (4%), insulin (basal, 3%; other 3%), others < 3%. CONCLUSIONS: First-line 
metformin was most commonly prescribed. Interestingly, despite the availability 
of newer agents classes (e.g., DDD4, GLP1s), most common second-line therapy was 
SU add-on to metformin or monotherapy. Contrary to popular beliefs, we observed 
no age-related differences in prescribing patterns. The outcomes and costs of such 
treatment patterns in the elderly relative to hypoglycemia and its sequelae war-
rants further evaluation.
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OBJECTIVES: To examine whether depression treatment is associated with health-
care expenditures among Medicaid beneficiaries with Type 2 Diabetes Mellitus 
(T2DM) and newly-diagnosed depression. METHODS: A retrospective longitudi-
nal repeated measures cohort design was used.Multi-year (2000-2008) three-state 
Medicaid data were used.The cohort included non-elderly, fee-for-service, continu-
ously enrolled Medicaid beneficiaries with T2DM and newly-diagnosed depression 
(N= 5,295).The depression diagnosis date was the “index-date”; baseline and fol-
low-up periods were defined as 12-months prior and subsequent to the index-date.
Depression treatment received in 120 days after index-date was categorized as, 
treatment with antidepressants only,psychotherapy only,both antidepressants and 
psychotherapy and no treatment.Total healthcare expenditures were calculated for 
each follow-up month.Linear mixed effects regressions on log transformed total 
expenditures were used to examine associations between depression treatment 
and monthly healthcare expenditures after adjusting for random intercept and 
fixed effects of time in months, depression treatment , types of co-existing chronic 
physical conditions (hierarchically classified based on their similarity to T2DM 
pathophysiology and/or management into dominant,concordant only,discordant 
only and both concordant and discordant), gender, age, race/ethnicity, other men-
tal health conditions, Medicaid eligibility due to poverty/medical need/waiver 
(yes/no), baseline healthcare utilization and county of residence characteristics 
such as presence of healthcare infrastructure( e.g.community mental health care 
clinic) and social determinants of health (e.g.county median income). RESULTS: 
Overall,57% had depression treatment (antidepressants only:27.3%, psychotherapy 
only:18.1% and both:11.4%). The average yearly expenditures were $30,590 for 
